SEC Form 4 · accession 0001179110-17-005914
Nabriva Therapeutics plc · NBRV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Period of report
Apr 6, 2017
Accepted (ET)
Apr 10, 2017 · 9:38 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001641640
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Apr 6, 2017 | S | 6,617 | $11.28 | D | 269,371 | D | |
| Common SharesF1 | Apr 6, 2017 | S | 24,600 | $11.20 | D | 244,771 | D | |
| Common SharesF1 | Apr 7, 2017 | S | 3,500 | $11.04 | D | 241,271 | D | |
| Common SharesF1 | Apr 7, 2017 | S | 18,001 | $10.96 | D | 223,270 | D | |
| Common SharesF1 | Apr 10, 2017 | S | 37,876 | $10.7311 | D | 185,394 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The prices reported in Column 4 are a weighted average prices. These shares were sold in multiple transactions.Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price.